Question · asked by 1 review

Clonazepam vs ethosuximide: Withdrawals due to adverse events

The review found no eligible studies for this question.

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
Clonazepam vs ethosuximide
Proportion of participants with TEAEs leading to discontinuation during the treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2022) · Cochrane Headline outcomes only
no estimate extractedNot reportedNo studies found
Clonazepam vs ethosuximide
Proportion of participants with TEAEs leading to discontinuation during the treatment period · people with newly diagnosed epilepsy
The review found no eligible studies for this question.
Clonazepam monotherapy for treating people with newly diagnosed epilepsy (2019) · Cochrane Headline outcomes onlyearlier version CD013028.PUB2, superseded
no estimate extractedNot reportedNo studies found

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
Clonazepam monotherapy for treating people with newly diagnosed epilepsy
2022 · Cochrane Headline outcomes only
Not reportedlist not extracted yetNot assessed

Studies behind the findings

None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.